Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
PDS-0101 by PDS Biotechnology for Head And Neck Cancer: Likelihood of Approval
PDS-0101 is under clinical development by PDS Biotechnology and currently in Phase II for Head And Neck Cancer. According to...
PDS-0101 by PDS Biotechnology for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
PDS-0101 is under clinical development by PDS Biotechnology and currently in Phase II for Recurrent Head And Neck Squamous Cell...
Risk adjusted net present value: What is the current valuation of PDS Biotechnology's PDS-0101?
PDS-0101 is a subunit vaccine commercialized by PDS Biotechnology, with a leading Phase II program in Vaginal Cancer;Vulvar Cancer. According...